Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Seminars in Oncology Nursing

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.soncn.2017.05.004PMID 28729120
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

  2019cited by this paper
• Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long‐term follow‐up in a single institution

  2016cited by this paper
• How I vaccinate blood and marrow transplant recipients.

  2016cited by this paper
• Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.

  2016cited by this paper
• Appendix: Multiple Myeloma Treatment Options for Newly Diagnosed, Relapsed, and Refractory Disease

  2016cited by this paper
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue

  2016cited by this paper
• 临床实践中治疗性单采术应用指南——基于美国血浆置换学会编写委员会的循证策略：第七版

  2016cited by this paper
• NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

  2016cited by this paper
• Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States

  2016cited by this paper
• Resources for Patients and Caregivers With Multiple Myeloma and Their Providers

  2016cited by this paper
• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

  2016cited by this paper
• Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant

  2016cited by this paper
• Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

  2016cited by this paper
• Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage.

  2016cited by this paper
• Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)

  2016cited by this paper
• Graft-Versus-Host Disease

  2016cited by this paper
• Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians

  2015cited by this paper
• CHAPTER 2 HEMATOPOIETIC STEM CELL TRANSPLANTATION : A MANUAL FOR NURSING PRACTICE 13 Basic Concepts of Transplantation

  2015cited by this paper
• American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip

  2015cited by this paper
• Comparison of upfront tandem autologous–allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma

  2015cited by this paper
• Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy.

  2015cited by this paper
• Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

  2015cited by this paper
• Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

  2015cited by this paper
• Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.

  2015cited by this paper
• High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.

  2015cited by this paper
• Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.

  2015cited by this paper
• American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip

  2015influential reference
• Autologous transplantation and maintenance therapy in multiple myeloma.

  2014cited by this paper
• Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma

  2014cited by this paper
• Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.

  2014cited by this paper
• Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.

  2014cited by this paper
• Reevaluating the neutropenic diet: time to change.

  2014cited by this paper
• Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future

  2014cited by this paper
• 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.

  2014cited by this paper
• How we manage autologous stem cell transplantation for patients with multiple myeloma.

  2014influential reference
• 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.

  2014cited by this paper
• Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation

  2013cited by this paper
• Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma

  2013cited by this paper
• Phase 2 trial of Intravenously Administered Plerixafor for Stem Cell Mobilization in Patients with Multiple Myeloma Following Lenalidomide Based Initial Therapy

  2013cited by this paper
• The changing landscape of multiple myeloma: implications for oncology nurses.

  2013cited by this paper
• Autologous hematopoietic stem cell transplantation for patients with multiple myeloma: an overview for nurses in community practice.

  2013influential reference
• Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

  2013cited by this paper
• Clinical updates in blood and marrow transplantation in multiple myeloma.

  2013influential reference
• Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

  2012cited by this paper
• Vaccination Recommendations for the Hematology and Oncology and Post–Stem Cell Transplant Populations

  2012cited by this paper
• Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.

  2012influential reference
• Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998–2006: factors associated with improved survival outcome

  2011cited by this paper
• International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.

  2010cited by this paper
• Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center

  2010cited by this paper
• Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma

  2009cited by this paper
• Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

  2009influential reference
• Hematopoietic stem cell transplantation: is ABO “A match made in heaven”?

  2009cited by this paper
• History of hematopoietic stem cell transplantation.

  2009cited by this paper
• Manual of Stem Cell and Bone Marrow Transplantation: Types of Transplantation

  2009influential reference
• Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.

  2009cited by this paper
• Late effects after autologous hematopoietic cell transplantation.

  2009cited by this paper
• Vaccination of hematopoietic cell transplant recipients

  2009cited by this paper
• Psychological issues of stem cell transplant.

  2009cited by this paper
• Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

  2009influential reference
• Acute complications of stem cell transplant.

  2009cited by this paper
• Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.

  2008cited by this paper
• Comparison of twin and autologous transplants for multiple myeloma.

  2008cited by this paper
• Vaccination of Hematopoietic Cell Transplant Recipients

  2007cited by this paper
• A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation

  2006cited by this paper
• Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

  2006cited by this paper
• Graft Versus Host Disease

  2005cited by this paper
• Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial.

  2001cited by this paper
• Standard therapy versus autologous transplantation in multiple myeloma.

  1997cited by this paper
• Supportive care: Editorial overview

  1992cited by this paper
• Neutropenia and infections in Felty's syndrome.

  1988cited by this paper
• High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma.

  1987cited by this paper
• High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.

  1986cited by this paper
• High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.

  1983cited by this paper
• BONE-MARROW TRANSPLANT IN AN IDENTICAL TWIN.

  1964cited by this paper

• Decision-making conflicts regarding hematopoietic stem cell transplantation in patients with hematological neoplasms: A descriptive qualitative study.

  2024cites this paper
• Investigating the effect of pre-transplant thrombocytopenia and anemia on the engraftment and long-term survival in multiple myeloma patients.

  2024cites this paper
• Comparison of pre- and posttransplant energy expenditure in patients undergoing hematopoietic stem cell transplantation and evaluation of associated factors.

  2023cites this paper
• Melanocyte stem cells in skin diseases and their potential in cell-based therapy.

  2022cites this paper
• Symptom prevalence and health-related quality of life in patients undergoing autologous stem cell transplantation - A longitudinal observational study.

  2021cites this paper
• Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma

  2021cites this paper
• Flat-dose granulocyte colony-stimulating factor evaluation after autologous hematopoietic stem cell transplant in multiple myeloma patients: Does one dose fit all?

  2020cites this paper
• The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium

  2020cites this paper
• Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years

  2019cites this paper
• Myeloma patients' experiences of haematopoietic stem cell transplant: A qualitative thematic synthesis.

  2018cites this paper
• Strategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients.

  2017cites this paper